跳至主要内容
临床试验/NCT00296569
NCT00296569已完成2 期

A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MK0686 in Patients With Osteoarthritis of the Knee or Hip

Merck Sharp & Dohme LLC0 个研究点目标入组 150 人开始时间: 2005年9月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
150
主要终点
Pain relief at the knee and hip over 4 weeks of treatment as assessed by the WOMAC Pain Subscale.

研究概览

简要总结

This study is being conducted to assess the safety and tolerability of MK-0686 and to evaluate its efficacy in the treatment of osteoarthritis of the hip or knee in men and women.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee,either prior NSAID or Acetaminophen users within the ARA functional class I,II or III and with no clinically significant diseases
  • Patients required to demonstrate a flare of the signs and symptoms of OA following withdrawal of NSAID treatment
  • Prior acetaminophen users also required to demonstrate greater than a defined minimum level of signs and symptoms of OA
  • females must be either post-menopausal or surgically sterilized

排除标准

  • No history of concurrent arthritic disease
  • No history of neoplastic disease within a specified duration
  • No history of disease that causes malabsorption
  • Chronic use of certain medications excluded

结局指标

主要结局

Pain relief at the knee and hip over 4 weeks of treatment as assessed by the WOMAC Pain Subscale.

时间窗: over 4 weeks of treatment

次要结局

  • Safety and tolerability over a 4-week treatment period(over a 4-week treatment period)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验